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Type I IFNs promote cellular responses to viruses, and IFN receptor (IFNAR) signaling regulates the responses of endothelial
cells of the blood-brain barrier (BBB) during neurotropic viral infection. However, the role of astrocytes in innate immune
responses of the BBB during viral infection of the CNS remains to be fully elucidated. Here, we have demonstrated that type I
IFNAR signaling in astrocytes regulates BBB permeability and protects the cerebellum from infection and immunopathology.
Mice with astrocyte-specific loss of IFNAR signaling showed decreased survival after West Nile virus infection. Accelerated
mortality was not due to expanded viral tropism or increased replication. Rather, viral entry increased specifically in the
hindbrain of IFNAR-deficient mice, suggesting that IFNAR signaling critically regulates BBB permeability in this brain region.
Pattern recognition receptors and IFN-stimulated genes had higher basal and IFN-induced expression in human and mouse
cerebellar astrocytes than did cerebral cortical astrocytes, suggesting that IFNAR signaling has brain region–specific roles
in CNS immune responses. Taken together, our data identify cerebellar astrocytes as key responders to viral infection and
highlight the existence of distinct innate immune programs in astrocytes from evolutionarily disparate regions of the CNS.

Introduction

Type I IFNs (IFNα/β) promote the expression of antiviral molecules in response to induction by several different transmembrane and cytosolic pattern recognition receptors (PRRs). Cellular
responses to type I IFNs depend on binding to the heterodimeric
receptor IFNAR, which initiates a signaling cascade that promotes
nuclear translocation of STAT1/2 heterodimers and transcriptional activation of IFN-stimulated genes (ISGs) (1). The rapid expression of hundreds of ISGs is critical for controlling viral infections,
as these proteins block viral entry, translation, transcription,
assembly, and egress (1–3). However, recent studies indicate that
IFNAR signaling also regulates other pathways that impact cellintrinsic antiviral functions. This is particularly evident in studies
of IFNAR signaling by cellular constituents of the blood-brain barrier (BBB) during neurotropic viral infection (4). The BBB, which
protects the CNS from pathogens, is composed of specialized
brain microvascular endothelial cells (BMECs) joined by tight
junctions (TJs) and ensheathed by pericytes and astrocyte endfeet
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(5). While IFNAR signaling in both BMECs and astrocytes contributes to TJ integrity in vitro (4), the in vivo contribution of IFNAR
signaling within astrocytes, which exhibit individual and regional
heterogeneity, has not been explored.
Innate immune mechanisms that regulate BBB function in the
setting of infectious diseases have been appreciated only recently.
Multiple inflammatory cytokines, including TNF-α, IL-6, IL-1β, and
IFN-γ, disrupt BBB and TJ integrity in BMECs through incompletely understood mechanisms (4, 6–8). Inflammatory cytokine signaling at the BBB during infection facilitates leukocyte trafficking into
the CNS, which is essential for clearance of many pathogens (9, 10).
However, this process may have pathological consequences, as the
CNS is susceptible to immune cell–mediated injury and possesses
a limited capacity for repair (11). Moreover, increased BBB permeability due to inflammatory cytokine signaling also may facilitate
viral neuroinvasion (6). Thus, cytokine signaling in BBB constituent cells must be regulated to protect the CNS from infection and
inflammation. In contrast to inflammatory cytokines, type I IFNs
stabilize BBB integrity and enhance TJ formation via balanced
activation of the small GTPases Rac1 and RhoA and by blocking
expression of IL-1β, which induces barrier disruption (4). Through
these actions, type I IFNs serve a protective function at the BBB by
counterbalancing the effects of inflammatory cytokines.
Astrocytes have critical roles in host defense during viral
infections of the CNS (12). PRR activation in astrocytes results in
the expression of many immune mediators, including inflammatory cytokines and type I IFNs (12, 13). During infection by pathojci.org   Volume 127   Number 3   March 2017

843

Downloaded from http://www.jci.org on April 17, 2017. https://doi.org/10.1172/JCI88720

RESEARCH ARTICLE

gens for which glia are not permissive targets, activation due to
pathogen recognition and/or abortive infection in astrocytes may
also promote antiviral immune responses of permissive neurons
as well as CNS leukocyte trafficking (6, 12, 14). Throughout the
CNS, astrocytes exhibit individual and regional heterogeneity in
gene expression, morphology, developmental ontogeny, and signaling functions (15). Although in vitro studies have established
the fact that astrocytes from different CNS regions respond
differently to pathogenic stimuli (16, 17), the contributions of
astrocyte heterogeneity to in vivo disease pathogenesis and host
defense are unknown.
In this study, we investigated how IFNAR signaling in astrocytes impacts the neuropathogenesis of West Nile virus (WNV)
encephalitis. Neurons are by far the preferred cellular target of
WNV throughout the CNS (12, 18, 19); in contrast, infection of glial
cells in vivo has not been well documented in mice and is probably rare (20). However, astrocyte activation and gliosis has been
observed in vivo during WNV infection (9, 21). Given the findings
from our own studies demonstrating that IFNAR signaling in astrocytes enhances in vitro BBB integrity in response to WNV (4), we
used Ifnarfl/fl Gfap-Cre mice, in which IFNAR signaling was abrogated in glial fibrillary acidic protein–expressing (GFAP-expressing)
astrocytes, to evaluate the contribution of astrocyte IFNAR signaling to WNV pathogenesis and disease. For these studies, we chose
the Gfap-Cre line 77.6, which was previously shown to exhibit a Cre
expression that is more specific to astrocytes than to other GfapCre lines (22–25). We also used an established in vitro BBB model
to examine how forebrain versus hindbrain astrocytes differentially regulate barrier function. A deficiency in astrocyte IFNAR signaling in mice with WNV encephalitis resulted in increased BBB permeability specifically within the hindbrain. WNV-infected Ifnarfl/fl
Gfap-Cre+ mice exhibited decreased survival without increased
viral replication or expanded tropism within hindbrain regions, but
sustained immunopathologic neuronal death that could be mitigated via functional blockade of the leukocyte adhesion molecule
VLA-4. Analysis of expression of PRRs and ISGs revealed higher
baseline and IFN-induced levels in human and mouse cerebellar
astrocytes compared with levels in cerebral cortical astrocytes.
Our findings demonstrate an unrecognized function for astrocyte
IFNAR signaling in the regulation of cerebellar BBB permeability and indicate that astrocytes from evolutionarily distinct CNS
regions show unique host defense programs.

Results

WNV infection in mice with global deletion of Ifnar leads to rapid
death due to virus-induced sepsis (26). To assess the specific role
of IFNAR signaling in astrocytes during WNV infection, we used
8-week-old Ifnarfl/fl Gfap-Cre+ and Ifnarfl/fl Cre– littermate controls.
Analysis of IFNAR expression in uninfected Ifnarfl/fl Gfap-Cre+
mice showed low expression of IFNAR in ALDH1L1+ astrocytes
in both the cerebral cortex (12.5%) and cerebellum (10.7%) compared with expression levels in controls (Supplemental Figure 1,
A and B; supplemental material available online with this article; https://doi.org/10.1172/JCI88720DS1). We did not observe
substantial deletion of Ifnar in nonastrocytic cells, as IFNAR
expression on ALDH1L1– cells remained intact compared with
levels detected in controls in both cerebral cortex (95.7%) and
844
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cerebellum (96.1%). Analysis of IFNAR expression on MAP2+ neurons and IBA1+ microglia also revealed no significant deletion of
Ifnar in these cell populations (Supplemental Figure 2, A and B).
IFNAR antibody specificity was confirmed by stains using an isotype control antibody as well as tissue derived from Ifnar1–/– mice
(Supplemental Figure 2C). We also observed similar levels of Cre
recombinase expression in both cerebral cortex and cerebellum
(Supplemental Figure 2D).
Following s.c. inoculation with 102 PFU of WNV (New York
2000 strain), Ifnarfl/fl Gfap-Cre+ mice had accelerated and enhanced
mortality (16.7% vs. 50.0% survival; Figure 1A) and greater clinical
signs of disease (Figure 1B) compared with Ifnarfl/fl Cre– controls. In
contrast, survival after WNV infection was unaffected in Ifnarfl/WT
Gfap-Cre+ littermates or in congenic Gfap-Cre+ mice that had never
been crossed with the Ifnarfl/fl line. As expected, viral burden did not
differ in any peripheral tissue compartments analyzed, including
serum, spleen, kidney, liver, and heart (Figure 1C and Supplemental
Figure 3), while viral burden in the CNS was significantly higher in
Ifnarfl/fl Gfap-Cre+ mice compared with Ifnarfl/fl Cre– controls. Virus
was detected earlier in cerebellar tissues in Ifnarfl/fl Gfap-Cre+ mice
on day 5 following infection (4 of 7 mice), when levels in Ifnarfl/fl
Cre– controls were undetectable (Figure 1D). By day 6, viral burden
in Ifnarfl/fl Gfap-Cre+ mice remained significantly higher in the cerebellum, while titers in the cerebral cortex and brainstem were elevated but did not reach statistical significance (P = 0.07 and 0.14,
respectively). By day 8, viral burden was significantly increased in
Ifnarfl/fl Gfap-Cre+ mice in all CNS regions analyzed, including the
cerebral cortex, brainstem, and spinal cord (Figure 1, D–G).
The early appearance of virus within the cerebellum of Ifnarfl/fl
Gfap-Cre+ mice suggested that astrocyte IFNAR signaling might
limit neuroinvasion at this site. As previous studies have suggested that early WNV neuroinvasion can be caused by defects in BBB
function (4, 27, 28), we determined whether BBB permeability
was altered differentially in the cerebellum and cerebral cortex of
Ifnarfl/fl Gfap-Cre+ mice compared with BBB permeability in Ifnarfl/fl
Cre– littermate controls. Analysis of extravasation of sodium fluorescein (376 Da) on various days following s.c. infection showed
biphasic kinetics, as observed in our previous studies (4, 21), with
an enhancement of BBB permeability on day 4 after infection,
decreased permeability on days 5 and 6, and a reopening of the BBB
on day 8 (Figure 1H). While loss of IFNAR signaling in astrocytes led
to enhancement of BBB permeability in both cerebral cortical and
cerebellar tissues after infection, the kinetics of these effects differed between regions. In the cerebral cortex, genotype differences
reached statistical significance only on days 6 and 8, whereas the
ability of the BBB to close on day 5 after infection was attenuated
significantly within the cerebellum (Figure 1H). Using immunohistochemical detection of extravasated endogenous IgG (150 kDa),
we observed enhanced BBB permeability to larger molecules on day
6 in the cerebellum but not the cerebral cortex (Figure 1, I and J).
The defect in BBB function on days 5 and 6 following infection coincided with the early detection of virus in the cerebellum, suggesting
that astrocyte IFNAR signaling in the cerebellum might be critical
for regulating BBB responses that limit viral neuroinvasion.
Apart from its regulation of BBB function, IFN signaling in
astrocytes may also serve protective antiviral functions for neurons
(14, 29), which might contribute to higher CNS titers at early time
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Figure 1. Survival and viral burden following s.c. WNV inoculation. (A–I) Mice were inoculated s.c. with WNV (New York 2000 strain). (A) Mice were
monitored daily for survival after infection. (B) Clinical scores of Ifnarfl/fl mice either positive or negative for Gfap-Cre (x axis) were recorded on the indicated
post-infection days. 0 = subclinical; 1 = hunched/ruffled fur; 2 = altered gate/slow movement; 3 = no movement, but responsive to stimuli; 4 = moribund;
5 = dead. (C) Serum viral loads as measured by qRT-PCR. (D–G) Tissue viral loads as measured by plaque assay. (H) BBB permeability was measured by
detection of sodium fluorescein accumulation in tissue homogenates derived from cerebral cortex or cerebellum. Data represent the mean ± SEM of
individual mouse values normalized to serum sodium fluorescein concentration. Group means were then normalized to the mean values for uninfected
controls. (I and J) Immunohistochemical detection of endogenous IgG accumulation in parenchymal CNS tissues. Signal intensities were quantified from
two ×40 fields per region using ImageJ software. Scale bar: 100 μm. Data in A and B represent pooled data collected from 3 independent experiments for
Ifnarfl/fl Cre– (n = 12), Ifnarfl/fl Gfap-Cre+ (n = 17), or Ifnar–/– (n = 8) mice. Data in C–G were collected from 2 to 3 independent experiments and represent values
recorded for 4 to 10 mice per time point. Data in G–I were pooled from a total of 5 mice per time point and were collected from 2 independent experiments.
*P < 0.05, **P < 0.01, and ***P < 0.001, by log-rank test (A), Mann-Whitney U test (C–G), or 2-way ANOVA (H and J).
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Figure 2. CNS replication and BBB permeability following intracranial inoculation. (A–D) Mice were inoculated with WNV (New York 2000 strain) via the
intracranial route, and CNS tissues were harvested on the indicated post-infection days. (A and B) Cerebral cortex and cerebellar tissues were collected
following intracranial inoculation within the cortex (A, intracortical inoculation) or cerebellum (B, intracerebellar inoculation). WNV titers were determined by
standard plaque assay. (C and D) Cerebral cortex and cerebellar tissues were analyzed for accumulation of sodium fluorescein in tissue parenchyma following
intracranial inoculation within the cortex (C, intracortical inoculation) or cerebellum (D, intracerebellar inoculation). Data represent the mean ± SEM of
individual mouse values normalized to serum fluorescein concentration. Group means were then normalized to mean values for uninfected controls. Data
in A–D were collected from 2 independent experiments and represent the mean values taken from a total of 5 mice per time point. Data were analyzed by
Mann-Whitney U test (A and B) or 2-way ANOVA (C and D). **P < 0.01.

points independently of enhanced neuroinvasion due to increased
BBB permeability. To differentiate these hypotheses, we infected
mice with WNV via an intracranial route, allowing us to bypass
barriers to neuroinvasion and measure the kinetics of viral replication in CNS neurons directly. Viral titers did not differ between
genotypes in cerebral cortical or cerebellar tissues following intracranial inoculation with 10 PFU of WNV, regardless of whether
virus was inoculated directly into the cerebral cortex (Figure 2A)
or cerebellum (Figure 2B). Similar results were obtained following intracerebellar inoculation with 10 PFU of WNV-Madagascar
(Supplemental Figure 4), an attenuated strain that is more IFN
sensitive than are highly pathogenic strains of WNV (30). Analogous to tissue titers, BBB permeability did not differ significantly
between genotypes following intracortical inoculation with WNV
(Figure 2C), although cerebellar tissues showed a trend toward
increased permeability. However, following intracerebellar inoculation, BBB closure was diminished significantly in the cerebellum
at early time points following infection of Ifnarfl/fl Gfap-Cre+ mice
compared with Ifnarfl/fl Cre – littermate controls (Figure 2D), suggesting that type I IFN signaling in astrocytes sustains BBB integrity following detection of WNV by cerebellar tissues. Importantly,
we observed no expansion of viral tropism to non-neuronal cells
in Ifnarfl/fl Gfap-Cre+ mice following either s.c. (data not shown) or
intracerebellar inoculation (Supplemental Figure 5), suggesting
that disease burden in these mice is not driven by an aberrant susceptibility of astrocytes and other glia to infection. Together, these
results suggest that higher viral titers in the cerebellum following
s.c. infection in Ifnarfl/fl Gfap-Cre+ mice are due to defects in BBB
restriction of neuroinvasion in the cerebellum during the early
stages of CNS infection.
846

jci.org   Volume 127   Number 3   March 2017

We questioned whether enhanced BBB permeability and
WNV neuroinvasion in the cerebellum of Ifnarfl/fl Gfap-Cre+ mice
were due to alterations in the regional expression of vasoactive
cytokines, including type I IFNs, TNF-α, and IL-1β, as our previous
studies showed that cytokine-mediated regulation of BBB permeability can directly influence WNV movement across endothelial barriers (4, 27, 28). On day 6 after s.c. inoculation with WNV,
control Ifnarfl/fl Cre– cerebellar tissues showed higher levels of
Ifnb (Figure 3A) and Ifna (Figure 3B) mRNA compared with cerebral cortex tissues with lower expression of the proinflammatory
cytokine Il1b (Figure 3C). In contrast, Ifnarfl/fl Gfap-Cre+ cerebellar tissues had higher levels of Il1b expression than did Ifnarfl/fl
Cre– littermate controls, whereas expression of this cytokine in the
cerebral cortex was unaffected by deletion of astrocytic Ifnar (Figure 3C). We observed no differences in Tnfa expression in either
genotype at this time point (Figure 3D). By day 8 after infection,
mRNA levels of type I IFNs, Il1b, and Tnfa were higher in tissues
from both the cerebral cortex and cerebellum of Ifnarfl/fl Gfap-Cre+
mice, which likely reflected the higher viral titers found across the
CNS at this time point (Figure 1, D–G). Differential cytokine gene
expression in these tissues was confirmed at the protein level by
ELISA (Supplemental Figure 6). These data suggest that enhanced
cerebellar BBB permeability and WNV neuroinvasion in Ifnarfl/fl
Gfap-Cre+ mice on day 6 (Figure 3, A and B) following s.c. infection are due in part to changes in the relative expression of barrierstabilizing (e.g., type I IFNs) versus barrier-disrupting (e.g., IL-1β)
cytokines (Figure 3, A and B versus Figure 3, C and D) (4).
During the course of these studies, we observed that expression of the inflammatory chemokines CCL2 and CXCL10, which
are produced by WNV-infected neurons (31), was higher in cerebel-
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Figure 3. Cytokine and chemokine expression in the CNS following s.c.
inoculation. (A–F) Mice were s.c. inoculated with WNV. Cerebral cortex
and cerebellar tissues were extracted on the indicated post-infection days.
Relative transcript levels in tissue homogenates were measured by SYBR
qRT-PCR for the indicated cytokines and chemokines. Data for individual
mice were normalized to Gapdh. Data represent the mean ± SEM from a
total of 5 to 6 mice and were collected from 2 independent experiments.
All data were analyzed by 2-way ANOVA. *P < 0.05 and ***P < 0.001.

lar tissues following infection, with Ifnarfl/fl Gfap-Cre+ mice showing even higher levels of Ccl2 and Cxcl10 expression in cerebellar
tissues (Figure 3, E and F) than were detected in their littermate
Ifnarfl/fl Cre – controls. Because of this result, we evaluated whether
the increased expression of leukocyte chemoattractant molecules
in Ifnarfl/fl Gfap-Cre+ mice resulted in differences in CNS immune
cell infiltration. Although the total number of infiltrating immune
cells in the cerebral cortex was unchanged in Ifnarfl/fl Gfap-Cre+
mice compared with the total number in Ifnarfl/fl Cre – controls on
day 8 following s.c. inoculation with WNV (Supplemental Figure
7A), there were greater numbers of CD8+ IFN-γ+ lymphocytes and
CD45hiCD11bloF4/80+ macrophages in the cerebellum (Supplemental Figure 7B). As enhanced inflammatory infiltrates may be a
secondary consequence of higher viral titers in Ifnarfl/fl Gfap-Cre+
mice following s.c. infection, we performed a similar analysis of
CNS immune infiltrates on day 6 following intracerebellar inoculation with WNV, as viral titers are indistinguishable between genotypes in this model. These experiments showed no significant
differences in immune cell infiltration between genotypes in the
cerebral cortex, but again revealed greater infiltration of several
leukocyte subsets (e.g., T lymphocytes and macrophages) in the
cerebellum of Ifnarfl/fl Gfap-Cre+ mice compared with Ifnarfl/fl Cre –
littermate controls (Figure 4, A and B). These data suggest that,
even in the presence of similar viral titers, type I IFN signaling in
cerebellar astrocytes suppresses neuroinflammation.
We questioned whether the increased immune infiltration in
the cerebellum of Ifnarfl/fl Gfap-Cre+ mice was a pathologic rather than protective response in the setting of astrocyte-specific

deficiency of IFNAR signaling. To assess this, we examined survival following intracranial inoculation with WNV. Although all
mice succumbed to infection in this model, intracranial infections allowed examination of the potential pathological impact
of enhanced immune infiltration in the absence of differential
viral titers. Remarkably, while intracortical inoculation with
WNV resulted in no significant difference in overall survival
rates between genotypes, Ifnarfl/fl Gfap-Cre+ mice had accelerated
mortality compared with Ifnarfl/fl Cre – controls following intracerebellar inoculation (Figure 4C). Immunohistochemical analysis
revealed a broad parenchymal distribution of CD3+ lymphocytes
(Figure 4D) and infiltrating IBA1+CD45hi myeloid cells (Supplemental Figure 7C) in the cerebella of infected Ifnarfl/fl Gfap-Cre+
mice on day 6 following intracerebellar inoculation. Infiltrating
CD3+ T cells were associated with TUNEL+ apoptotic cells, especially in Ifnarfl/fl Gfap-Cre+ mice, which had higher numbers of
apoptotic neurons and astrocytes compared with numbers detected in Ifnarfl/fl Cre– controls (Figure 4, E and F).
As type I IFN regulates immune trafficking by modulating
VCAM-1 (CD106) expression on neurovascular cells (32–34), we
determined whether the enhanced neuroinflammation in Ifnarfl/fl
Gfap-Cre+ mice was associated with increased VCAM-1 expression. While VCAM-1 expression increased across the CNS following WNV infection, Vcam-1 mRNA levels were further increased
in the cerebellum but not in the cerebral cortex of Ifnarfl/fl GfapCre+ mice compared with Ifnarfl/fl Cre – controls on days 6 and 8
after s.c. inoculation (Figure 5A and Supplemental Figure 8A).
IFN-β treatment of either human or mouse primary astrocyte
cultures from the cerebellum, but not from the cerebral cortex,
significantly downregulated VCAM-1 expression (Figure 5B and
Supplemental Figure 8B). Immunohistochemical analysis following intracerebellar inoculation of Ifnarfl/fl Gfap-Cre+ mice revealed
no genotype-dependent differences in VCAM-1 expression in the
cerebral cortex (Figure 5C). In contrast, Ifnarfl/fl Gfap-Cre+ cerebellar tissues showed enhanced VCAM-1 expression that was
distributed across multiple cell types, including endothelial cells
and astrocytes (Figure 5D). While VCAM-1 expression on vascular
endothelium is a well-known regulator of neuroinflammation (35),
VCAM-1 expression on astrocytes has also been shown to promote
neuroinflammation by enhancing the penetration of infiltrating
leukocytes out of perivascular spaces and into the CNS parenchyma (36, 37). Moreover, pharmacological blockade of VCAM-1
binding to its ligand VLA-4 has previously been shown to decrease
pathogenic neuroinflammation and improve survival following
s.c. WNV infection (38). Given that IFNAR signaling in astrocytes
downregulated VCAM-1 expression in the cerebellum following
WNV infection, we questioned whether VCAM-1 expression contributed to the enhanced immune infiltration and immunopatholjci.org   Volume 127   Number 3   March 2017
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Figure 4. CNS immune cell trafficking and immunopathology following intracranial inoculation. (A and B) Flow cytometric analysis of CNS immune cell
infiltrates on day 6 following intracerebellar infection. (A) Representative flow cytometric dot plots demonstrating the percentages of CD45hi versus CD45lo
brain leukocytes isolated from the cerebral cortex and cerebellum of mock- and WNV-infected mice. The representative panel for mock infection is for an
Ifnarfl/fl mouse, which resembles mock infection in Gfap-Cre+ mice (shown here). The numbers indicate the percentage of each cell type within the total
number of cells isolated (after exclusion of doublets and dead cell debris). (B) Total number of CD45+ leukocytes, CD45hiCD4+ and CD45hiCD8+ lymphocytes
expressing IFN-γ, and CD45loCD11b+F4/80+ microglia and CD45hiCD11b+F4/80+ macrophages isolated from the indicated brain region. Data in B were collected
from 2 independent experiments and represent the mean ± SEM for 6 mice. Note that data in A and B were not normalized for the greater tissue volume
of the cerebral cortex versus the cerebellum. (C) Survival was monitored following either intracortical or intracerebellar inoculation. Survival data for 10 to
11 mice per group were pooled from 2 independent infections. (D and E) Immunohistochemical detection of TUNEL+ nuclei of dead and dying cells in the
cerebellar granule cell layer, costained for CD3+ T lymphocytes (D), NeuN+ neurons (E), or S100-β+ astrocytes (E). Scale bars: 50 μm. (F) Quantification of dead
and dying neurons (TUNEL+NeuN+) or astrocytes (TUNEL+S100-β+), generated by counting cells that were double positive for TUNEL and the appropriate cell
marker (depicted in pixel-masked images to the right of the merged RGB images in E). Data were determined by counting 4 images from 2 nonserial sections
per mouse (n = 5 mice/group). Counts for each image were normalized to the total area of the granule cell layer present per high-power field. Graphed data
points represent averages for all images taken for individual mice. All data represent pooled values from 2 independent experiments and were compared
using an unpaired, 2-tailed Student’s t test (B and F) or log-rank test (C). *P < 0.05 and **P < 0.01. All error bars are SEM.
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Figure 5. VCAM-1 expression in cerebellar
astrocytes in vitro and in the CNS in vivo
following infection. (A and B) Vcam-1 mRNA
levels were detected by SYBR qRT-PCR. (A)
Vcam-1 mRNA levels were detected in the
cerebella of mice taken on the indicated days
following s.c. infection. (B) VCAM-1 mRNA
levels in primary adult human cerebellar
astrocytes and primary murine neonatal
cerebellar astrocytes following a 4-hour
treatment with 10 U/ml IFN-β. Ct values in
A and B were normalized to the Ct values
of the housekeeping gene Gapdh. (C and D)
Immunohistochemical detection of VCAM-1
expression on CD31/endomucin+ (cocktail+)
endothelial cells and S100-β+ astrocytes in
the cerebral cortex (C) or cerebellum (D).
Scale bars: 50 μm. VCAM-1 expression on
the indicated cell type was quantified as the
mean VCAM-1 (green) fluorescence intensity of pixels that stained positive for the
indicated cell marker. Data were obtained
after quantifying 4 images from 2 randomly
chosen, nonserial sections per mouse (81,000
μm2 total analyzed area per mouse, 5 mice
per group). Data are reported as log10 arbitrary
fluorescence intensity units. Data in A–D are
from 2 independent experiments and are
representative images or the mean ± SEM of
5 to 6 replicates per mouse per group.
***P < 0.001, by 2-way ANOVA.

ogy observed in Ifnarfl/fl Gfap-Cre+ mice. Thus, we tested whether
blockade of VCAM-1–VLA-4 binding would protect Ifnarfl/fl GfapCre+ mice following WNV infection. Daily administration of a
small-molecule antagonist of VLA-4 (BIO5192) starting on day
4 following intracerebellar infection extended survival in Ifnarfl/fl
Gfap-Cre+ mice, without impacting survival in the Ifnarfl/fl Cre– littermate controls (Figure 6A). Flow cytometric analysis on day 6
after infection revealed that BIO5192 treatment modestly reduced

the number of infiltrating lymphocytes and macrophages in Ifnarfl/fl
Cre– littermates, with only differences in macrophage numbers
reaching statistical significance (Figure 6B). In contrast, VLA-4
blockade significantly reduced infiltrating lymphocyte and macrophage numbers in Ifnarfl/fl Gfap-Cre+ cerebella to levels indistinguishable from those detected in littermate controls. BIO5192
treatment also reduced the numbers of TUNEL+ neurons and
astrocytes (Figure 6, C and D) in the cerebella of Ifnarfl/fl Gfap-Cre+
jci.org   Volume 127   Number 3   March 2017
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Figure 6. Survival, immune infiltrates, and immunopathology following pharmacological blockade of VLA-4. (A–D) Mice were inoculated via an intracerebellar route with WNV. Infected mice in all experiments were treated i.p. with 10 mg/kg BIO5192, a small-molecule VLA-4 antagonist, or vehicle solution
beginning on day 4 after infection. (A) Survival was monitored daily following infection (n = 7 mice/group). (B) Flow cytometric analysis of immune
infiltrates in the cerebellum on day 6 after infection (n = 4 mice/group) (C) Immunohistochemical detection of TUNEL+ neurons (NeuN, left) and astrocytes
(S100-β, right) in cerebellar granule cell layers of infected mice on day 6 after infection. Scale bar: 50 μm. (D) Quantification of dead and dying neurons (left
panel) or astrocytes (right panel), generated by counting cells double positive for TUNEL and the appropriate cell marker (depicted in pixel masked images
to the right of merged RGB images). Data are taken from counting 4 images from 2 nonserial sections per mouse (5 mice/group). Counts for each image
were normalized to the total area of granule cell layer present per high-power field. All data represent pooled values from 2 independent experiments.
*P < 0.05 , **P < 0.01, and ***P < 0.001, by log-rank test (A) or 2-way ANOVA (B and D).

mice on day 6 after infection. Thus, blockade of VCAM-1 in Ifnarfl/fl
Gfap-Cre+ mice following WNV infection decreased inflammation and immunopathology specifically in the cerebellum. These
data indicate that enhanced expression of leukocyte migratory
cues and the resultant neuroinflammation contribute directly to
the enhanced CNS tissue injury and animal mortality observed in
Ifnarfl/fl Gfap-Cre+ mice following intracranial WNV infection.
In light of these findings, we next assessed whether IFN signaling in astrocytes from the cerebellum and cerebral cortex dif850
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ferentially impacts BBB function. We generated in vitro BBB cultures in which primary murine BMECs derived from the cerebral
cortex were cocultured on inserts above astrocytes derived from
the cerebellum or cerebral cortex. Measurements of BBB integrity were taken by recording transendothelial electrical resistance
(TEER), as described previously (4). While in vitro BBB cultures
with cerebral cortex or cerebellar astrocytes did not exhibit baseline differences in TEER, the addition of IFN-β to the bottom
chamber resulted in an enhancement of TEER in cultures with
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cerebellar astrocytes, beyond that observed in cultures with astrocytes from the cerebral cortex (Figure 7A).
To assess whether astrocytes derived from different brain
regions could influence the ability of WNV to cross an intact BBB,
we generated in vitro BBB cultures composed of uniform cultures
of WT BMECS grown on inserts above either WT or Ifnar–/– astrocytes derived from either the cerebral cortex or cerebellum. WNV
was placed into the top chamber of the cultures for 6 hours, after
which viral trafficking was measured by extracting and combining
RNA from the supernatants and astrocytes of the bottom chambers. We observed less viral trafficking to the bottom chambers
of the cultures with WT cerebellar astrocytes than to those with
WT cerebral cortical astrocytes (Figure 7B). However, we did not
observe this difference when astrocytes were deficient in IFNAR.
Pretreatment of cultures with IFN-β effectively limited viral trafficking across in vitro BBB in all cultures, consistent with our previous report showing synergistic effects of IFN signaling in endothelial cells and astrocytes on the modulation of WNV trafficking
in vitro (4). However, IFN-β treatment suppressed viral trafficking
more robustly in cultures with WT cerebellar astrocytes than in
those with cerebral cortex astrocytes, and this difference was lost
when astrocytes lacked IFNAR expression (Figure 7B), suggesting
that cerebellar astrocytes are better able than are cerebral cortical
astrocytes to positively regulate BBB function following stimulation with type I IFN.
Given the differences in the efficacy of IFN signaling in astrocytes derived from different brain regions, we explored whether
IFN signaling programs in astrocytes from these regions were different. We compared transcript levels of canonical ISGs between
human astrocytes derived from the cerebral cortex and cerebellum. Remarkably, we observed enhanced basal expression of
several ISGs, including the PRR TLR7, the transcription factor
IFN regulatory factor 3 (IRF3), and other major antiviral or proinflammatory genes (IFN-induced protein with tetratricopeptide
repeats 1 [IFIT1], 2′-5′-oligoadenylate synthetase 1 [OAS1], and
C-X-C motif chemokine ligand 11 [CXCL11]) (Figure 7, C–H). In
contrast, basal expression of other PRR and signaling molecules
(e.g., TLR3 and IRF7) did not differ between the 2 types of astrocytes (data not shown). Moreover, astrocytes derived from the
cerebellum exhibited enhanced expression of ISGs after 4 hours
of treatment with IFN-β, though by 24 hours, both astrocyte populations reached expression levels equivalent to those of most
ISGs. These data suggest that astrocytes from the cerebellum are
primed at baseline with enhanced type I IFN signatures compared
with astrocytes from the cerebral cortex and reach maximal ISG
expression more rapidly following IFN stimulation. This pattern
was not unique to human astrocytes. While baseline expression of
the type I and type III IFN receptors IFNAR1 and IFNLR1 did not
differ, we observed higher basal and IFN-induced expression of
ISG mRNAs and proteins in primary murine cerebellar astrocytes
compared with expression levels in those from the cerebral cortex
(Supplemental Figure 9, A–I).
To generate a more complete picture of differential gene
expression, we next performed mRNA sequencing (RNA-seq)
in primary human astrocytes from either brain region following 4 hours of treatment with IFN-β or a PBS vehicle. Our analysis of global gene expression revealed substantial differential

gene expression between astrocytes from cerebral cortex and
those from cerebellum across both treatment conditions (Figure
7I). Pathway analysis of these genes revealed that many relevant
pathways were differentially regulated in astrocytes from either
region, including IFN signaling and IRF activation of cytosolic
PRRs (Supplemental Table 1). Of note, other potentially important
pathways that exhibited differential regulation included innate
immune pathways such as death receptor signaling and retinoic
acid–mediated apoptosis; moreover, pathways relevant to BBB
biology, including TJ signaling and adherens junction signaling,
were also differentially regulated across regions. Further analysis
confirmed our previous finding that homeostatic and IFN-induced
expression of ISGs and PRRs was higher in cerebellar astrocytes
than in astrocytes from cerebral cortex (Supplemental Tables 2
and 3). Examples of IFN-related genes expressed more highly in
cerebellar astrocytes include Ifit1, Ifit2, Ifit3, IFN-induced with
helicase C domain 1 (Ifih1, also known as MDA5), IFN-γ–inducible protein 16 (Ifi16), IFN-induced protein 44 like (Ifi44l), MX
dynamin-like GTPase 1 (Mx1), radical S-adenosyl methionine
domain–containing 2 (Rsad2, also known as viperin), and Stat1.
While not every gene identified in our quantitative reverse transcription PCR (qRT-PCR) studies met the threshold for statistical
significance in our RNA-seq analysis, these studies confirm broad
differential regulation of innate immune and IFN signaling pathways in astrocytes isolated from cerebellum compared with those
from cerebral cortex.

Discussion

Alterations in BBB biology and function during neurotropic viral
infection have been presumed to arise from uniform responses of
BMECs throughout the CNS vasculature. In this study, we demonstrate that innate immune responses of astrocytes from evolutionarily distinct regions of the CNS contribute to BBB heterogeneity via differential activation of antiviral signaling pathways.
Our studies indicate differential roles for type I IFN signaling in
hindbrain and forebrain astrocytes, as loss of IFNAR signaling in
astrocytes resulted in enhanced BBB permeability, early viral neuroinvasion, and increased immunopathologic neuronal cell death
in the cerebellum of mice following WNV infection. Studies using
both human and mouse astrocytes showed enhanced basal and
IFN-induced expression of PRRs and ISGs in cerebellar astrocytes
compared with expression levels in cortical astrocytes, suggesting
that cerebellar astrocytes are primed for more rapid IFN responses upon detection of CNS pathogens, leading to greater enhancement of BBB function and suppression of neuroinflammation.
These findings increase our understanding of the immunologic heterogeneity of the CNS. A growing body of research has
established the differential susceptibility of CNS regions to infection and autoimmunity (15, 18, 31, 39), though the resident CNS
cells and signaling pathways that underlie these heterogeneities
remain poorly understood. As an example, neurons of hindbrain
and forebrain regions exhibit differential type I IFN signaling in
response to positive-strand RNA viruses (18), and, in general, type
I IFN responses to viruses vary among neuronal subtypes and their
stages of differentiation (18, 40–42). While nonspecific neuronal
deletion of Ifnar in our study could confound analyses of similar
regional phenotypes in astrocytes, the Gfap-Cre line 77.6 has been
jci.org   Volume 127   Number 3   March 2017
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Figure 7. Type I IFN responses in astrocytes in vitro. (A and B) In vitro BBB Transwell cultures were generated with either cerebral cortical or cerebellar
astrocytes. (A) TEER recordings in cultures treated with saline vehicle or 10 U/ml recombinant IFN-β. (B) Cultures were generated with cerebral cortical or
cerebellar astrocytes (x axis) derived from either WT (black bars) or Ifnar–/– mice (orange bars) and treated overnight with either saline vehicle or 10 U/ml
recombinant IFN-β. Following pretreatment, WNV (0.01 MOI) was added to the top chamber of cultures and allowed to migrate for 6 hours. Data represent
combined WNV genome copy numbers detected in the astrocyte monolayer and bottom chamber supernatant. (C–H) Primary human cerebral cortical
or cerebellar astrocytes were treated with 10 U/ml recombinant IFN-β and analyzed for transcript expression of the indicated genes 4 and 24 hours after
treatment. Ct values for all genes were normalized to Ct values of the housekeeping gene GAPDH. (I) Primary human cerebral cortical or cerebellar astrocytes were treated for 4 hours with PBS or 10U/ml recombinant IFN-β and subjected to RNA-seq. Heatmap and histogram of global gene expression across
regions and treatment groups were generated from all statistically significant genes. Data in A–H represent the mean ± SEM of 5 to 6 replicates from 2
to 3 independent experiments and were analyzed by 2-way ANOVA. Data in I were derived from 3 independent samples per group and were analyzed as
described in the Methods. *P < 0.05 , **P < 0.01, and ***P < 0.001. Cbl, cerebellum; Ctx, cortex.
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shown in numerous studies to have reliably astrocyte-specific
expression (22–25). Consistent with this, we observed deletion
of Ifnar on cortical and cerebellar astrocytes, with intact expression of the receptor on nonastrocytic cells. The lack of alterations
in virologic and immunologic parameters in the periphery or
after intracortical inoculation of virus also suggests that there is
little nonspecific deletion of Ifnar in neurons or peripheral cells.
Although regional heterogeneity in astrocyte neurophysiologic functions has been appreciated (15, 43, 44), few studies have
evaluated the differential responses of these astrocytes to viral
infections. Our study suggests that differential IFN signaling in
hindbrain regions is multicellular in nature and may be common
to all cells of neuroectodermal lineage in the hindbrain. The confirmation of these findings in neurons and astrocytes from both
murine and human sources suggests a phenomenon that may be
conserved in recent evolution and that perhaps serves to protect
centers of vital autonomic function in the cerebellum and brainstem from pathogenic and immunologic injury.
Our findings highlight the multifaceted contributions of astro
glia to the regulation of CNS immune responses. Loss of IFNAR
signaling in astrocytes has multiple consequences, including the
enhanced expression of inflammatory cytokines and chemokines,
which can disrupt the BBB during neurotropic viral infection (4, 6,
7). This enhanced BBB permeability is associated with earlier detection of WNV in hindbrain regions of the CNS, suggesting that astrocyte IFNAR signaling prevents or delays infection at this site. Altered
expression of cytokines such as IL-1β also probably influences other
functions of the BBB, including local antigen presentation (21, 45)
and perivascular capture of infiltrating leukocytes (9, 46), as reflected by the broad parenchymal localization of CD3+ lymphocytes in
our study. Regional differences in astrocyte signaling may also differentially impact regional differences in other neurovascular cell
types, including endothelial cells. While WNV may enter the CNS
via multiple mechanisms, including nonhematogenous routes such
as retrograde axonal transport (47) and transynaptic trafficking (48),
the critical role of BBB function in limiting WNV neuroinvasion and
subsequent disease burden has been established in many recent
studies (4, 27, 28). Moreover, sciatic nerve ligation ipsilateral to the
footpad used for s.c. inoculation does not rescue CNS infection or
mortality in mice (47), suggesting that hematogenous spread alone
is sufficient for severe neuroinvasive infection. Thus, the alterations
to BBB function observed in our study probably contributed significantly to the enhanced disease pathogenesis we observed in Ifnarfl/fl
Gfap-Cre+ mice following WNV infection.
IFNAR signaling in astrocytes was important for the suppression of VCAM-1 expression in neurovascular cells of the hindbrain.
A potential mechanism for this effect is type I IFN–mediated suppression of inflammatory cytokines. For example, several recent
studies have described a role for type I IFN in suppressing the
expression of IL-1β (4, 49, 50), which is known to induce VCAM-1
expression in astrocytes (51, 52). VCAM-1–VLA-4 interactions
facilitate immune trafficking during CNS infection (38, 53).
Although CNS immune infiltration is required for viral clearance
following WNV infection (9, 54), high levels of inflammatory cell
infiltration are associated with pathology and bystander injury (11,
45, 55). Thus, astrocyte IFNAR–mediated suppression of VCAM-1
expression appears to play a protective antiinflammatory role in

hindbrain tissues. This role is supported by studies demonstrating
that pharmacological blockade of VLA-4 in the context of neurotropic viral infection can ameliorate disease, largely via suppression of CNS immunopathology (38, 53). We note, however, that
the experimental consequences of VLA-4 blockade are likely context dependent, varying by disease model and timing of treatment
after infection, and that this blockade may act through additional
VLA-4 ligands beyond VCAM-1, including JAM-B and fibronectin
(56). Moreover, modulation of VCAM-1 is likely only one of several relevant regulatory outputs of type I IFN signaling in astrocytes
and probably acts in concert with independent effects on inflammatory cytokine expression and BBB function to coordinate neuroinflammation during WNV infection.
Our study demonstrating a role for astrocytes in limiting
inflammation via the regulation of BBB permeability has clinical
implications. Loss of BBB integrity in the hindbrain, as evidenced
by gadolinium contrast–enhanced magnetic resonance imaging
(Gd-MRI), is associated with poor prognosis in patients with WNV
neuroinvasive disease (19, 57). As Gd-MRI–enhanced lesions
develop in conjunction with inflammatory infiltrates, alteration in
vascular permeability is believed to occur in tandem with the capture and trafficking of leukocytes from the blood at endothelial barriers (58, 59). Indeed, recent studies indicate that increased BBB
permeability predicts the development of neuroinflammation in
patients with CNS autoimmunity (60). Although impaired VLA-4
function is known to jeopardize host protection during acute viral
infection of the CNS (61), our study suggests that patients with
acute WNV encephalitis and persistent cerebellar inflammation
and disease symptoms might benefit from VLA-4 blockade. In
summary, these findings advance our understanding of astrocyte
innate immune responses during viral infection, identify regionally distinct roles for astrocytes in the regulation of BBB function,
and suggest that defining signaling pathways that modulate leukocyte entry into distinct brain regions can identify new targets for
the prevention and treatment of CNS immunopathology.

Methods

Mouse models of WNV encephalitis. All animals used in this study were
infected at 8 weeks of age. The Gfap-Cre+ line 77.6 was obtained commercially from The Jackson Laboratory and maintained in the hemizygous state. Ifnarfl/fl mice were obtained from R. Schreiber (Washington
University School of Medicine, St. Louis, Missouri, USA) and U. Kalinke (Paul-Ehrlich-Institut, Hannover, Germany). Ifnarfl/fl mice (62)
were backcrossed using speed congenic analysis to 99% C57BL/6J
as judged by microsatellite analysis. All animals were housed under
specific pathogen–free conditions. Littermates for the survival studies performed and depicted in Figure 1A were derived from crosses of
Ifnarfl/WT Gfap-Cre+ with Ifnarfl/fl breeders. Subsequently, littermates
were obtained from breeders on a homozygous Ifnarfl/fl background
(Ifnarfl/fl Gfap-Cre+/– with Ifnarfl/fl). Inoculation via footpad s.c. injection (50 μl) or intracranial inoculation (10 μl) was performed with
either 102 or 10 PFU of WNV, respectively, as previously described
(63). WNV (strain 3000.0259, isolated in New York in 2000) (64) was
used in all experiments except those depicted in Supplemental Figure
5, in which the WNV-Madagascar (strain DakAnMg798, isolated in
1978) (65) also was used. Viral titers in all studies were assessed via
plaque assay in BHK21-15 cells, as previously described (66).
jci.org   Volume 127   Number 3   March 2017

853

Downloaded from http://www.jci.org on April 17, 2017. https://doi.org/10.1172/JCI88720

RESEARCH ARTICLE

Immunohistochemical analysis. CNS tissue sections were
obtained after cardiac perfusion with 4% paraformaldehyde in PBS.
Tissues were frozen, blocked, and stained as previously described
(31) with primary antibodies against IFNAR1 (BioLegend; 127305);
S100-β (Abcam; ab41548); CD31/endomucin antibody cocktail
(BD, 550274 and eBioscience, 14-5851-81) (67); VCAM-1 (Abcam;
ab134047); ALDH1L1 (Abcam; ab52492); NeuN (EMD Millipore;
MAB277B); and CD3 (Abcam; ab16044). Secondary fluorescence
staining was performed with the appropriate Alexa Fluor 488 and
555 antibodies (Life Technologies, Thermo Fisher Scientific). Nuclei
in all preparations were stained with TO-PRO-3 (Life Technologies,
Thermo Fisher Scientific). TUNEL staining was performed with a
TMR Red In Situ Cell Death Detection Kit (Roche). All images were
acquired via confocal microscopy (Carl Zeiss). Image analysis was
performed with ImageJ software (NIH). Details on individual analyses are provided in the figure legends.
In vivo assessment of BBB permeability. Sodium fluorescein permeability experiments were performed as previously described (4).
Briefly, on predetermined days following infection, mice were injected i.p. with 100 μl of 100 mg/ml fluorescein sodium salt (SigmaAldrich) in sterile PBS. Tissue homogenates and serum were collected following perfusion with PBS and then incubated overnight in 2%
TCA (Sigma-Aldrich) to precipitate protein. Supernatants were diluted in equal volumes of borate buffer, pH 11.0 (Sigma-Aldrich). Tissue
fluorescence values were determined with a fluorometric plate reader
and standardized against plasma fluorescence values for individual
mice. Fluorescence staining for extravasated endogenous IgG was
performed as previously described (27).
CNS leukocyte isolation and flow cytometric analysis. Leukocytes
were isolated from freshly dissected CNS regions following PBS perfusion and stained with fluorescently conjugated antibodies to CD3,
CD4, CD8β, CD11b, F4/80, and CD45 as previously described (21).
Intracellular IFN-γ staining was performed on isolated leukocytes in
an I-Ab–restricted NS3-2066 and NS3-1616 peptide and a Db-restricted NS4B peptide restimulation assay as previously described (27). An
LSR Flow Cytometer (BD) and FlowJo software (Tree Star) were used
for data acquisition and analysis.
qRT-PCR analysis. Total RNA was collected from freshly dissected CNS regions following PBS perfusion or from cell cultures using an
RNeasy Kit (QIAGEN) according to the manufacturer’s instructions.
Reverse transcription and SYBR Green qRT-PCR were performed for
cytokine, chemokine, and ISG analytes as previously described (31). Ct
values for all genes were normalized to Ct values of the housekeeping
gene GAPDH. Data from qRT-PCR experiments are reported as ΔCt
(Cttarget – CtGAPDH). Primers used for all analyses are reported in Supplemental Table 4. qRT-PCR analysis of WNV copy numbers in serum and
cell culture supernatants was performed with TaqMan reagents (Thermo
Fisher Scientific) as previously described (27, 66).
Western blotting. Protein lysates were collected in radioimmunoprecipitation assay (RIPA) buffer (Sigma-Aldrich), separated on NuPage 4%–12% Bis-Tris Gels (Invitrogen, Thermo Fisher Scientific), and
transferred to nitrocellulose membranes via the iBlot 2 transfer system
(Thermo Fisher Scientific). Membranes were incubated overnight at
4ºC in TBS plus 4% powdered milk with the following primary antibodies: anti-IFIT1 mAb (13B4-1, unpublished antibody developed in
the laboratory of Michael Diamond); anti-IFIT2 polyclonal antibody
(Thermo Fisher Scientific; PA3-845); and anti–β actin mAb (Cell Sig854
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naling Technology; 93700P). Membranes were washed 3 times with
water, followed by a 3-hour incubation at room temperature with
anti-mouse DyLight 800 (Thermo Fisher Scientific; 52575) and goat
anti-rabbit IRDye 680RD (LI-COR; 925-68071) secondary antibodies. Membranes were washed 3 times with TBS Tween-20 (TBST) and
imaged using the Odyssey Gel Imaging System (LI-COR).
Astrocyte and in vitro BBB cultures. Primary cerebral cortex and
cerebellar human astrocytes were obtained from ScienCell Research
Laboratories (catalogs 1800 and 1810) and grown according to the
manufacturer’s protocols in ScienCell Astrocyte Medium (catalog
1801). Primary neonatal mouse astrocytes were obtained and maintained as previously described (4). Immunohistochemical characterization of primary human and murine astrocytes using anti–S100-β
(Abcam; ab41548) and anti-ALDH1A1 (Abcam; ab52492) antibodies
in conjunction with nuclear stains (TO-PRO-3) revealed a greater than
99% purity. In vitro BBB cultures were generated with primary mouse
BMECs and astrocytes and used in TEER and viral migration assays as
previously described (4, 27).
IFN treatment. Astrocyte and in vitro BBB cultures were treated in
normal culture medium with 10 U/ml mouse or human recombinant
IFN-β (PBL Assay Sciences) or 0.1% BSA in PBS vehicle, as appropriate. Cytokines were added to the bottom chamber of in vitro BBB cultures. Endothelial cells and astrocytes remained in coculture for the
duration of the cytokine treatment.
VLA-4 blockade studies. The VLA-4 antagonist BIO5192 (Tocris
Bioscience) was reconstituted in aqueous vehicle containing ethanol
and propylene glycol as described previously (56). A daily dosage of 10
mg/kg was chosen on the basis of published studies of serum half-life
and receptor occupancy (56, 68). All injections were given i.p. beginning on day 4 after WNV infection.
RNA-seq. Human astrocytes from cerebral cortex or cerebellum
were cultured and treated for 4 hours with PBS or recombinant IFN-β
as described above. Total RNA was extracted using an RNeasy Kit
(QIAGEN) and prepared for sequencing. Raw RNA-seq data (FASTQ
files) were demultiplexed and checked for quality (FASTQC), and
adapters and rRNA were digitally removed (cutadapt, version 1.8.3 and
Bowtie2, version 2.2.5). Sufficient reads were generated (~30 million
reads) and then mapped to the human genome (NCBI build 37.1). Raw
reads were aligned to the host genome using STAR (2.4.2) and then
converted into gene counts with HTSeq (version 0.6.0). Gene counts
were filtered by a mean of 10 or greater across all samples. Exploratory analysis and statistics were run using the R statistical programming
language (version 3.2.0). The gene count matrix was normalized using
voom through the Bioconductor limma package (version 3.26.9). Statistical analysis (including differential expression) was performed
using R and Bioconductor. Sequencing data were deposited in the
NCBI’s Gene Expression Omnibus (GEO) database (GEO GSE89476).
Statistics. Survival experiments were analyzed by log-rank test.
Viral titers in tissue were analyzed by Mann-Whitney U test. Other
experiments were analyzed with parametric tests (2-tailed Student’s t
test or 2-way ANOVA), with correction for multiple comparisons where
appropriate. All statistical analysis except for RNA-seq analysis was performed using GraphPad Prism Version 7 software (GraphPad Software).
A P value of less than 0.05 was considered statistically significant.
Study approval. All experiments were performed in compliance
with and under the approval of the Washington University Animal
Studies Committee.
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